Contact


Mailing Address

Donate

Your tax deductible gift in any amount helps support our efforts to advocate for more research, better treatments, and ultimately, a cure for IH.

Donate

 

Author:hfadmin

Arise Clinical Trial

CLINICAL TRIAL ENROLLING PATIENTS WITH IDIOPATHIC HYPERSOMNIA AND NARCOLEPSY TYPE 2 Balance Therapeutics is evaluating an investigational new drug BTD-001, to treat excessive daytime sleepiness in individuals diagnosed with Idiopathic Hypersomnia (IH) or Narcolepsy Type 2 (Na-2).  A Phase 2 clinical trial is currently enrolling Na-2 subjects at 26...

Continue Reading

Get “Somnusnooze”, HF’s monthly newsletter

Sign up to receive HF updates, news from the world of sleep research, first-person stories, and more.

Thank you for your interest in the Hypersomnia Foundation!